The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Perova N.V.

National Research Center for Preventive Medicine, Petroverigsky per. 10, Moscow, 101990 Russia

Atheromarkers of high-density lipoproteins. Part II. Impairments in the composition, structure, and functions of high-density lipoproteins as both the cause of their atherogenic properties and their atheromarkers: a review of literature

Authors:

Perova N.V.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2017;20(4): 37‑44

DOI: 10.17116/profmed201720437-44

Views: 670

Downloaded: 16

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Perova NV. Atheromarkers of high-density lipoproteins. Part II. Impairments in the composition, structure, and functions of high-density lipoproteins as both the cause of their atherogenic properties and their atheromarkers: a review of literature. Russian Journal of Preventive Medicine. 2017;20(4):37‑44. (In Russ.)
https://doi.org/10.17116/profmed201720437-44

 
МСФ на ЯМ
Close metadata

Investigations of high-density lipoproteins (HDL) isolated from the blood of patients with coronary heart disease, type 2 diabetes mellitus, rheumatic and kidney diseases, and metabolic syndrome revealed dysfunction of HDL in the replacement of their proteins (primarily apoA-1) with other proteins that had no atheroprotective properties. The displacement of the antioxidant protein paraoxonase 1 from the particles of HDL leads to the loss of the antioxidant effect of the latter particularly on low-density lipoproteins and arterial wall endothelium, as well as anti-inflammatory action, that of inhibition of the enzyme nitric oxide (NO) synthase and production of the vasodilator NO, as well as regulatory action on platelets. Posttranslational modifications of proteins and modifications of the lipid components reducing the anti-atherogenic functions of HDL were found. The ultimate goal of studies of HDL, which is the possible effective use of the latter to obtain recombinant forms that could be used for therapeutic or preventive purposes, has not yet been achieved, but the causes of transformation of classical anti-atherogenic HDL into their atherogenic forms were identified. These data are the basis for creating a diagnostic system, namely, a panel of «atheromarkers of HDL».

Keywords:

high-density lipoproteins
HDL
anti-atherogenicity
modifications of proteins and lipids
atheromarkers

Authors:

Perova N.V.

National Research Center for Preventive Medicine, Petroverigsky per. 10, Moscow, 101990 Russia

List of references:

  1. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, LaDu BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96 2758-2767.
  2. Bergt C, Pennathur S, Fu X, Byun J, O’Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA. 2004;101:13032-13037.
  3. Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD and Kinter M Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem. 2005;280:38-47.
  4. Holzer M, Gauster M, Pfeifer T, Wadsack C, Fauler G, Stiegler P, Koefeler H, Beubler E, Schuligoi R, Heinemann A, Marsche G. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal. 2011;14:2337-2346.
  5. Zhou H, Tan KC, Shiu SW, Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant. 2008;23:927-933.
  6. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller MR, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Lüscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-2708.
  7. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kra¨nkel N, Kania G, 1 ... Eckardstein A, Lu¨scher TF, Fliser D, Bahlmann FH, Landmesser U. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38:754-768.
  8. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res. 1985;26:1389-1398.
  9. De Beer MC, Ji A, Jahangiri A, Vaughan AM, de Beer FC, van der Westhuyzen DR, Webb NR. ATP binding cassette G1-dependent cholesterol efflux during inflammation. J Lipid Res. 2011;52:345-353.
  10. van der Westhuyzen DR, Cai L, de Beer MC, de Beer FC. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J Biol Chem. 2005;280:35890-35895.
  11. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): Influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995;36:1058-1065.
  12. Marsche G, Frank S, Raynes JG, Kozarsky KF, Sattler W, Malle E. The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. Biochem J. 2007;402:117-124.
  13. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol. 2000;20:763-772.
  14. Gordon SM, Davidson WS, Urbina EM, Dolan LM, Heink A, Zang H, Lu LJ, Shah AS.The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth. Diabetes. 2013;62:2958-2967.
  15. Puranik R, Bao S, Nobecourt E, Nicholls SJ, Dusting GJ, Barter PJ, Celermajer DS, Rye KA. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis. 2008;196:240-247.
  16. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Lüscher TF, and Landmesser U. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: Role of high-density lipoprotein-proteome remodeling. Circulation. 2013;127:891-904.
  17. Vaisar T, Mayer P, Nilsson E, Zhao XQ, Knopp R, Prazen BJ. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta. 2010;411:972-979.
  18. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A, Marsche G. Uremia alters HDL composition and function. J Am Soc Nephrol. 2011;22:1631-1641.
  19. Vuilleumier N, Dayer JM, von Eckardstein A, Roux-Lombard P. Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins? Swiss Med Wkly. 2013;143:w13781.
  20. Shao B. Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL. Biochim Biophys Acta. 2012;1821:490-501.
  21. Rudolph V, Keller T, Schulz A, Ojeda F, Rudolph TK, Tzikas S, Bickel C, Meinertz T, Münzel T, Blankenberg S, Baldus S. Diagnostic and prognostic performance of myeloperoxidase plasma levels compared with sensitive troponins in patients admitted with acute onset chest pain. Circ Cardiovasc Genet. 2012;5:561-568.
  22. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529-541.
  23. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, McDonald TO, Brunzell J, Chait A, Oram JF, O’Brien K, Geary RL, Heinecke JW. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem. 2004;279:42977-42983.
  24. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176-1184.
  25. Wu Z, Wagner MA, Zheng L, Parks JS, Shy JM III, Smith JD, Gogonea V, Hazen SL. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol. 2007;14:861-868.
  26. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci USA. 2008;105:12224-12229.
  27. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, Hazen SL. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem. 2009;284:30825-30835.
  28. Aldini G, Vistoli G, Stefek M, Smith JD, DiDonato JA, Hazen SL.l. Molecular strategies to prevent, inhibit and degrade advanced glycoxidation and advanced lipoxidation end products. Free Radic Res. 2013;47(Suppl 1):93-137.
  29. Kurosaki Y, Tsukushi T, Munekata S. Akahoshi T, Moriya T, Ogawa Z. Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus. J Clin Lab Anal. 2013;27:231-236.
  30. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia. 2007;50:643-653.
  31. Mastorikou M, Mackness B, Liu Y, Mackness M. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med. 2008;25:1049-1055.
  32. Schwedhelm E, Boger RH. The role of asymmetric and symmetric dimethylarginines in renal diseases. Nat Rev Nephrol. 2011;7:275-285.
  33. Batuca JR, Ames PR, Isenberg DA, Alves JD. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann NY Acad Sci. 2007;1108:137-146.
  34. Vuilleumier N, Bas S, Pagano S, Montecucco F, Guerne P-A, Finckh A, Lovis Ch, Mach F, Hochstrasser D, Roux-Lombard P, Gabay C. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2010;62:2640-2650.
  35. Vuilleumier N, Reber G, James R, Burger D, de Moerloose P, Dayer JM. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun. 2004;23:353-360.
  36. Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez J-C, Burkhard PR, Mensi N, Righini M, Reber G, James R, Mach F, Chevrolet J-C, Dayer J-M, Frostegard J, Roux-Lombard P. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci (Lond). 2008;115:25-33.
  37. Keller PF, Pagano S, Roux-Lombard P, Sigaud P, Rutschmann OT, Mach F, Hochstrasser D, Vuilleumier N. Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardia infarction. J Intern Med. 2012;271:451-462.
  38. Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V, Pelli G, Kovari E, Pane B, Spinella G, Pende A, Palombo D, Dallegri F, Mach F, Roux-Lombard P. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J. 2011;32:412-421.
  39. Vuilleumoer N, Rossier MF, Pagano S, Python M, Charbonney E, Nkoulou R, James R, Reber G, Mach F, Roux-Kombard P. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J. 2010;31(7):815-823.
  40. Srivastava R, Yu S, Yu S, Parks BW, Black LL, Kabarowski JH. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase-1 activity in systemic lupus erythematosus-prone gld mice. Arthritis Rheum. 2011;63:201-211.
  41. Pagano S, Satta N, Werling D, Offord V, DeMoerloose P, Charbonney E, Hochstrasser D, Roux-Lombard P, Vuilleumier N. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. J Intern Med. 2012;272:344-357.
  42. Перова НВ, Метельская ВА, Ануфриева НВ,Щербакова ИА, Нечаев А.С, Грацианский НА Субфракционный спектр липопротеинов высокой плотности и их холестерин — транспортирующие свойства. [Perova NV, Metelskaya VA, Anufrieva NV, Scherbakova IA, Nechaev AS, Shishova AM, Shakhov YA, Gratsianski NA Subfractional spectrum of high density lipoproteins and their cholesterol — transporting properties. Eds. Levy RI et al. Athеroclerosis Reviews. New York: Raven Press. 1988;17:29-38.
  43. Ottestad I, Halvorsen Bente, Balstad Trude Rakel, Otterdal Kari, Borge Grethe, Iren Andersen, Brosstad Frank, Myhre Anne Grete, Ose Leiv, Nenseter Marit S, Holven Kirsten Bjørklund. Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux. J Nutr. 2006;136(4):877-881.
  44. Greene DJ, Skeggs JW, Morton RE. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type-I (SR-BI). J Biol Chem. 2001;276:4804-4811.
  45. Nobécourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, Kontush A. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: Relationship to elevated oxidative stress and hyperglycaemia. Diabetologia. 2005;48:529-538.
  46. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman. MJ, Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004;89:4963-4971.
  47. Balstad TR, Holven KB, Ottestad IO, Otterdal K, Halvorsen B, Myhre AM, Ose L, Nenseter MS. Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function. Clin Chim Acta. 2005;359:171-178.
  48. Persegol L, Verges B, Foissac MP, Duvillard L. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2006;49:1380-1386.
  49. Gelissen IC, Rye KA, Brown AJ, Dean RT, Jessup W. Oxysterol efflux from macrophage foam cells: The essential role of acceptor phospholipid. J Lipid Res. 1999;40:1636-1646.
  50. Karuna R, Holleboom AG, Motazacker MM, Kuivenhoven JA, Frikke-Schmidt R, Tybjaerg-Hansen A. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis. 2011;214:448-455.
  51. Steiner C, Holleboom AG, Karuna RR, Motazacker MM, Kuivenhoven JA, Frikke-Schmidt R, Lipoprotein distribution and serum concentrations of 7alpha-hydroxy-4-cholesten-3-one and bile acids: Effects of monogenic disturbances in high-density lipoprotein metabolism. Clin Sci (Lond). 2012;122:385-396.
  52. Badeau RM, Metso J, Wähälä K, Tikkanen MJ, Jauhiainen M. Human macrophage cholesterol efflux potential is enhanced by HDL-associated 17beta-estradiol fatty acyl esters. J Steroid Biochem Mol Biol. 2009;116:44-49.
  53. Gong M, Wilson M, Kelly T, Su W, Dressman J, Kincer J, Matveev SV, Guo L, Guerin T, Li XA, Zhu W, Uittenbogaard A, Smart EJ. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest. 2003;111:1579-1587.
  54. Paatela H, Mervaala E, Deb S, Wahala K, Tikkanen MJ. HDL-associated dehydroepiandrosterone fatty acyl sters: Enhancement of vasodilatory effect of HDL. Steroids. 2009;74:814-818.
  55. Yancey PG, de la Llera-Moya M, Swarnaker S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, Rothblat GH. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and netment of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem. 2000;275:36596-36604.
  56. Deguchi H, Fernandez JA, Hackeng TM, Banka CL, Griffin JH. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci USA. 2000;97:1743-1748.
  57. Vila A, Korytowski W, Girotti AW. Spontaneous transfer of phospholipid and cholesterol hydroperoxides between cell membranes and low-density lipoprotein: Assessment of reaction kinetics and prooxidant effects. Biochemistry. 2002;41:13705-13716.
  58. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res. 2000;41:1261-1267.
  59. Buonacorso V, Nakandakare ER, Nunes VS, Passarelli M, Quintao EC, Lottenberg AM. Macrophage cholesterol efflux elicited by human total plasma and by HDL subfractions is not affected by different types of dietary fatty acids. Am J Clin Nutr. 2007;86:1270-1277.
  60. De Vries R, Beusekamp BJ, Kerstens MN, Groen AK, Van Tol A, Dullaart RPF. A low-saturated-fat, low-cholesterol diet decreases plasma CETP activity and pre beta-HDL formation but does not affect cellular cholesterol efflux to plasma from type 1 diabetic patients. Scand J Clin Lab Invest. 2005;65:729-737.
  61. Gillotte KL, Lund-Katz S, de la Llera-Moya M, Parks JS, Rudel LL, Rothblat GH, Phillips MC. Dietary modification of high density lipoprotein phospholipid and influence on cellular cholesterol efflux. J Lipid Res. 1998;39:2065-2075.
  62. Marsche G, Heller R, Fauler G, Kovacevic A, Nuszkowski A, Graier W, Sattler W, Malle E. 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol. 2004;24:2302-2306.
  63. Blache D, Gautier T, Tietge UJ, Lagrost L. Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high density lipoproteins through a phospholipase A2-dependent mechanism. FASEB J. 2012;26:927-937.
  64. de la Llera MM, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, Tabita-Martinez J, Wolfe ML, Badellino K, Pruscino L, Mehta NN, Asztalos BF, Reilly MP Inflammation modulates human HDL compositionand function in vivo. Atherosclerosis. 2012;222:390-394.
  65. Shamburek RD, Zech LA, Cooper PS, Vandenbroek JM, Schwartz CC. Disappearance of two major phosphatidylcholines from plasma is predominantly via LCAT and hepatic lipase. Am J Physiol. 1996;271:E1073-E1082.
  66. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G. Suppression of endothelial cell apoptosis by HDL and HDL-associated lysosphingolipids. J Biol Chem. 2001;276:34480-34485.
  67. Sevastou I, Kaffe E, Mouratis MA, Aidinis V. Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta. 2013;1831:42-60.
  68. Martinez-Beamonte R, Lou-Bonafonte JM, Martinez-Gracia MV, Osada J. Sphingomyelin in high-density lipoproteins: Structural role and biological function. Int J Mol Sci. 2013;14:7716-7741.
  69. Horter MJ, Sondermann S, Reinecke H, Bogdanski J, Woltering A, Kerber S, Breithardt G, Assmann G, Von Eckardstein A. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol Scand. 2002;176:123-130.
  70. Argraves KM, Sethi AA, Gazzolo PJ, Wilkerson BA, Remaley AT, Tybjaerg-Hansen A, Nordestgaard BG, Yeatts SD, Nicholas KS, Barth JL, Argraves WS.. S1P, dihydro-S1P and C24: 1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011;10:70.
  71. Sattler KJ, Elbasan SKJ, Keul P, Elter-Schulz M, Bode C, Gräler M.H., Bröcker-Preuss M, Budde T, Erbel R, Heusch G, Levkau B. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol. 2010;105:821-832.
  72. Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I, Kuivenhoven JA, Rohrer L, Matile H, Hornemann T, Stoffel M, Rentsch KM, von Eckardstein A. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis. 2011;219:855-863.
  73. Damiano MG, Mutharasan RK, Tripathy S, McMahon KM, Thaxton CS. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev. 2013;65:649-662.
  74. Liu X, Suo R, Xiong SL, Zhang QH, Yi GH. HDL drug carriers for targeted therapy. Clin Chim Acta. 2013;415:94-100.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.